A novel protein regulates cancer immunity and could offer a therapeutic target

The protein moesin could be a target for cancer immunotherapy. New data suggest that moesin promotes conversion of naive T cells into regulatory T cells that suppress the immune response against cancer. Inhibiting moesin could help restore the anti-tumor T cell response and also improve the survival of cancer-killing CD8+ cells after adoptive T cell transfer.